Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370068 | 0.88 | MAP2K4 (0.48) | MAP2K4KDM4EHPGDPTGER1RORC | |
| SCHEMBL6375165 | 0.84 | PTGER1 (0.51) | MAP2K4KDM4EHPGDPTGER1RORC | |
| SCHEMBL6370428 | 0.84 | MAP2K4 (0.47) | MAP2K4KDM4EHPGDTP53PTGER1 | |
| SCHEMBL6369989 | 0.83 | MAP2K4 (0.43) | MAP2K4KDM4EHPGDGAAPTGER1 | |
| SCHEMBL6370616 | 0.82 | MAP2K4 (0.57) | MAP2K4PTGER1RORCJAK2JAK1 | |
| SCHEMBL6369555 | 0.82 | MAPK8 (0.47) | MAP2K4PTGER1RORC | |
| SCHEMBL6370071 | 0.82 | MAP2K4 (0.46) | MAP2K4KDM4EHPGDPTGER1RORC | |
| SCHEMBL6370625 | 0.82 | MAPK8 (0.51) | MAP2K4KDM4EHPGDTP53GAA | |
| SCHEMBL6375104 | 0.81 | MAP2K4 (0.58) | MAP2K4TP53PTGER1LMNAHTT | |
| SCHEMBL6369571 | 0.80 | MAP2K4 (0.45) | MAP2K4KDM4EHPGDTSHRPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAP2K4 2785/4885KDM4E 3563/4885HPGD 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.